Claudia Schlegel

Humaniche is an ETH Zürich spin-off in formation, developing a family of off-the-shelf and disease-specific human bone marrow niche proxy kits and in vitro systems that provide structured insights into efficacy and hematopoietic toxicity at the stage immediately prior to first-in-human trials, where development risk and capital exposure are highest. Until now, it has raised CHF 588K in non-dilutive funding. By introducing functional human bone marrow biology into late preclinical decision-making, Humaniche reduces costly late-stage clinical failures and supports the pharmaceutical industry’s transition toward validated New Approach Methodologies (NAMs). By developing human-relevant, scalable, and reproducible bone marrow disease model tools, Humanishe aims to enable safer, more effective advanced therapies to efficiently reach blood cancer patients.